Table 2.

Factors associated with initiating curative treatment among study participants

		All patients (N=519)			Patients with HIV only (n=357)
		Model 1			Model 2
		Model 1	Model 1a	Model 1b
Variables		Crude OR (95% CI)	Adjusted OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)
Age	≤ 61 years	1.00	1.00	1.00	1.00	1.00
	> 61 years	0.52 (0.33–0.80)	0.43 (0.24–0.75)	0.43 (0.24–0.77)	1.02 (0.44–2.40)	0.91 (0.34–2.42)
Marital status	Single	1.00	1.00	1.00	1.00	1.00
	Married/partnered	1.35 (0.89–2.04)	1.52 (0.94–2.45)	1.54 (0.95–2.49)	1.32 (0.78–2.25)	1.28 (0.71–2.31)
	Divorced/widowed	1.07 (0.64–1.82)	1.27 (0.68–2.38)	1.34 (0.71–2.54)	1.35 (0.63–2.90)	1.58 (0.65–3.85)
HIV status	Uninfected	1.00	1.00	N/A	N/A	N/A
	Infected		0.91 (0.55–1.49)	N/A	N/A	N/A
Baseline CD4, cells/μL	HIV uninfected	1.00	N/A	1.00	N/A	N/A
	≤ 200	0.62 (0.26–1.46)	N/A	0.48 (0.18–1.29)	1.00	1.00
	> 200	1.61 (1.08–2.40)	N/A	1.25 (0.74–2.12)	2.59 (1.12–6.01)	2.84 (1.14–7.09)
Stage	Stage 3, 4	1.00	1.00	1.00	1.00	1.00
	Stage 1, 2	3.71 (2.52–5.45)	3.24 (2.15–4.87)	3.36 (2.21–5.11)	3.35 (2.11–5.33)	3.16 (1.92–5.19)
	Missing	0.10 (0.03–0.32)	0.08 (0.02–0.26)	0.09 (0.03–0.29)	0.13 (0.04–0.44)	0.13 (0.04–0.47)
Baseline hemoglobin, g/dL	< 10 g/dL	1.00	1.00	1.00	1.00	1.00
	≥ 10 g/dL	1.89 (1.32–2.71)	1.75 (1.15–2.65)	1.85 (1.21–2.83)	1.74 (1.14–2.67)	1.63 (0.99–2.69)
Baseline creatinine, μmol/L		0.998 (0.996–1.000)	0.999 (0.997–1.001)	0.999 (0.998–1.001)	0.999 (0.998–1.001)	1.00 (0.999–1.001)
Performance status	≤ 80	1.00	1.00	1.00	1.00	1.00
	> 80	1.64 (1.08–2.50)	1.04 (0.64–1.69)	1.02 (0.62–1.68)	1.75 (1.02–2.98)	1.32 (0.71–2.45)
Distance in km		1.000 (0.999–1.001)	Not included in model	Not included in model	1.000 (0.999–1.001)	Not included in model

Abbreviations: OR=Odds ratio; CI=Confidence interval.

Model 1a: HIV+ vs. HIV−

Model 1b: HIV− vs HIV+ by CD4 count ≤ 200 vs. >200 cells/μl

Model 2: HIV+ only with CD4 count ≤ 200 vs. >200 cells/μl